Genomics stocks closed sharply lower on Wednesday as the biotech sector tumbled for a second day due to profit-taking following the long holiday weekend, analysts said.

Celera Genomics (NYSE: CRA) closed at 100 7/16, down 4 1/16, or 3.9 percent, following a 7 percent drop on Tuesday. Incyte Genomics (Nasdaq: INCY) ended the session down 2 1/16, or 5.4 percent, at 36 1/2 following a 4.2 percent decline the previous day. And Affymetrix (Nasdaq: AFFX) shed 4 15/16, or 6.6 percent, to close at 70 on the heels of a 5.1 percent decline on Tuesday.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.